Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease
- PMID: 9007159
Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease
Abstract
Most patients with Parkinson's disease develop response fluctuations after several years of chronic treatment with levodopa. Accumulating evidence suggest that pharmacokinetic mechanisms are the cause of some subtypes of response fluctuations, especially the "delayed-on" and "no-on" phenomena. Evaluation of gastric emptying in Parkinson patients with and without response fluctuations revealed that those with fluctuations had a significant delay in gastric emptying compared to patients without fluctuations. Treatment with cisapride, a prokinetic drug, causes amelioration of these fluctuations. The optimal solution is to bypass the stomach completely and deliver levodopa parenterally. This was done by levodopa ethylester injections, which reduced latency to "on" and prolonged "on" duration in patients with severe response fluctuations. These data emphasize the role of the stomach as one of the causes for deterioration in Parkinson's disease.
Similar articles
-
Effect of cisapride on response fluctuations in Parkinson's disease.Mov Disord. 1995 Jan;10(1):81-4. doi: 10.1002/mds.870100113. Mov Disord. 1995. PMID: 7885359 Clinical Trial.
-
Irregular gastrointestinal drug absorption in Parkinson's disease.Expert Opin Drug Metab Toxicol. 2008 Feb;4(2):193-203. doi: 10.1517/17425255.4.2.193. Expert Opin Drug Metab Toxicol. 2008. PMID: 18248312 Review.
-
Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease.Ann Neurol. 1996 Mar;39(3):400-4. doi: 10.1002/ana.410390321. Ann Neurol. 1996. PMID: 8602763 Clinical Trial.
-
Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.Br J Clin Pharmacol. 2004 Nov;58 Suppl 1(Suppl 1):41-9. doi: 10.1111/j.1365-2125.2004.01799.x. Br J Clin Pharmacol. 2004. PMID: 15496222 Free PMC article. Clinical Trial.
-
[Optimisation of treatment of Parkinson's disease with levodopa].Neurol Neurochir Pol. 2009 Sep-Oct;43(5):446-59. Neurol Neurochir Pol. 2009. PMID: 20054747 Review. Polish.
Cited by
-
Levodopa availability improves with progression of Parkinson's disease.J Neurol. 2006 Sep;253(9):1221-6. doi: 10.1007/s00415-006-0207-y. Epub 2006 Apr 28. J Neurol. 2006. PMID: 16649094 Clinical Trial.
-
Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat.J Pharmacokinet Pharmacodyn. 2008 Feb;35(1):1-30. doi: 10.1007/s10928-007-9073-1. Epub 2007 Oct 26. J Pharmacokinet Pharmacodyn. 2008. PMID: 17963025
-
Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease.Exp Neurol. 2007 Sep;207(1):4-12. doi: 10.1016/j.expneurol.2007.05.010. Epub 2007 May 18. Exp Neurol. 2007. PMID: 17586496 Free PMC article.
-
Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss.Acta Neuropathol. 2012 Nov;124(5):665-80. doi: 10.1007/s00401-012-1040-2. Epub 2012 Sep 2. Acta Neuropathol. 2012. PMID: 22941241 Free PMC article.
-
Perioperative sublingual levodopa in Parkisnon's Disease: A useful alternative!Indian J Anaesth. 2017 May;61(5):432-434. doi: 10.4103/ija.IJA_178_17. Indian J Anaesth. 2017. PMID: 28584355 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical